under the Australian SAS. Our long-term goal is represented by our multifaceted pharmaceutical research program being undertaken to pursue patents, and FDA registration, in up to 4 therapeutic products. 3 of those research programs have commenced studies and we expect more study results to be received and shared with our investors imminently”.
IHL Price at posting:
8.1¢ Sentiment: Buy Disclosure: Held